Alexion Pharmaceuticals, Inc.

Director, U.S. Federal and State Health Policy and Access, Rare Disease

Alexion Pharmaceuticals, Inc.  •  $166k/yr  •  Washington, DC (Hybrid)  •  10 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Director, U.S. Federal and State Health Policy and Access, Rare Disease

Washington, D.C

Alexion Corporate Affairs

Hybrid Work- on average 3 days a week from office

A bility to travel up to 25%

This role leads the development and execution of an integrated U.S. health policy strategy aligned with AstraZeneca enterprise priorities to support patient access, advance launch and lifecycle readiness, and enable long-term innovation for Alexion’s rare disease portfolio. The role is integral to the success of the U.S. Commercial organization.

You'll sit at the intersection of health policy and regulatory policy, shaping federal and state environments to enabletimelyandappropriate patientaccess to innovative therapies, particularly for complex and next-generation treatments, including cell and gene therapies.

What you'll do

U.S. Health Policy Strategy & Environment Shaping

  • Lead the development and execution of a comprehensive U.S. federal and state health policy strategy aligned to Alexion’s rare disease portfolio and enterprise priorities.

  • Shape the external policy environment to support innovation, sustainability, and patient access for rare disease therapies.

  • Identifyand address systemic policy barriers across diagnosis, referral pathways, treatment initiation, andcarecoordination.

  • Anticipate and influence policyneeds foradvanced and next-generation therapies, including cell and gene therapies.

  • Develop andmaintainpolicy positions that support the long-term growth and sustainability of the rare disease ecosystem.

  • Lead and coordinate a “one team” Alexion view on policy, impacts, and strategies; serve as the primary Alexion representative in broader AstraZeneca working groups to ensure calibration and unified positions.

Policy Integration with Access, Regulatory, and Lifecycle Strategy

  • Serve as primary health policy partner to Market Access, ensuring federal and state policy considerations are integrated into brand and lifecycle planning.

  • Translate evolving policy and regulatory dynamics into strategic implications for coverage, reimbursement, and patient access, without direct ownership of access strategy execution.

  • Partner with Regulatory Affairs to ensure alignment between health policy strategy and regulatory policy priorities, translating regulatory developments into broader policy implications.

  • Support alignment on integrated policy approaches across FDA, CMS, and state regulators, while respecting functional ownership.

  • Provide policy input to support launch readiness and lifecycle planning, including identification of risks, opportunities, and mitigation strategies.

External Engagement, Advocacy & Stakeholder Leadership

  • Lead engagement with federal andstatepolicymakers, regulators, and agencies (e.g., CMS, HHS, state Medicaid programs) to shape policiesimpactingrare disease.

  • Partner withFederal and StateGovernment Affairs to drive coordinated advocacy strategies, legislative engagement, and policy campaigns.

  • Lead engagement with trade groups and policy coalitions, and partner with Patient Advocacy, Global Patient Experience, and Medical Affairs teams to support engagementwith externalstakeholders

  • Support policy approaches that enable provider readiness, diagnostic pathways, and coordinated care for rare disease patients.

Strategic Insight, Evidence & Enterprise Alignment

  • Identifykey evidence gaps relevant to policy and access decision-making and partner cross-functionally to inform evidence generation priorities.

  • Leverage data, real-world evidence, and insights to support policy positioning and external engagement.

  • Provide actionable policy insights and recommendations to U.S. leadership to inform business strategy and decision-making.

  • Monitor and assess emerging policy trends,establishingearly warning systems and scenario planning for key risks (e.g., IRA, Medicaid, 340B,PBM reforms, andutilizationmanagement).

  • Ensure alignment across Corporate Affairs, Market Access, Regulatory, Medical, and Commercial teams, supporting integrated enterprise positions.

Essential for the role

  • Bachelor’s degree
  • 8+ years of experience in health policy or government affairs
  • Pharmaceuticalexperiencein a healthcare policy,reimbursementor market access or, payer experience (CMS, health plan,PBM), or related healthcare policy consulting,lawor financial/actuarial firm
  • Expertisein U.S.federal and statehealth policy affecting rare disease or specialty medicines.
  • Knowledge of Medicare, Medicaid, Marketplace, VA, DoD, 340B and Commercial programs and payer policies, reimbursement processes, and reimbursement coding inclusive of strategy development
  • Experience engaging external stakeholders and alliances.
  • Strong strategic, analytical, and communication skills(oral and written)

Desirable for the role

  • Advanced degree(eg.,MBA JD, MHA, MPH).

  • Strong knowledge of FDA regulatory frameworks and approval pathways (NDA, BLA, accelerated approval, priority review, REMS, labeling, post marketing commitments).

  • Experience working in a matrixed organization.

  • Experience partnering with Market Access and Regulatory Affairs.

Office Working Requirements

When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. That’s why we work, on average, a minimum of three days per week from the office. But that doesn’t mean we’re not flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.

The annual base pay for this position ranges from $ 166,324.00 - 249,486.00 USD. Our positions offer eligibility for various incentives—an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans. ​

#LI-Hybrid ​

Date Posted

19-May-2026

Closing Date

01-Jun-2026

Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.

Alexion Pharmaceuticals, Inc.

About Alexion Pharmaceuticals, Inc.

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease.

A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.

As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.

Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.

GL/NP/0116

GL/NP/0095

Community Guidelines: https://bit.ly/39x9gqy

Industry
Biotech & Life Sciences
Company Size
5,001-10,000 employees
Headquarters
Boston, Massachusetts
Year Founded
1992
Social Media